Home

Grant C. Bogle

CIK 1646675 · President and CEO · last filed 2026-07-15

Grant C. Bogle is a President and CEO who has filed 18 SEC Form 4 insider transactions across 3 companies since 2015. The most recent filing, for NUVL, was dated Jul 15, 2026. Across all open-market trades the lifetime net is −$2.3M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

18

Lifetime Open-Market Net

-$2.27M

Filer Profile

Reported Address
C/O TESARO, INC.
1000 WINTER STREET, SUITE 3300
WALTHAM, MA 02451
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Nuvalent, Inc. (NUVL) Delisted Director 0 $123.96 $0 $0 4 2026-07-15
Epizyme, Inc. (EPZM) Delisted See Remarks 259,170 $1.47 $381.0K $0 7 2022-08-11
TESARO, Inc. (TSRO) Delisted Sr. VP, Chief Commercial Ofc 0 — — -$2.27M 6 2019-01-22

Recent Filings

18 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-15 Nuvalent, Inc. (NUVL) Delisted Mixed −9,291 -$460.5K EDGAR
2026-06-18 Nuvalent, Inc. (NUVL) Delisted Grant (A) +3,444 $0 EDGAR
2025-06-20 Nuvalent, Inc. (NUVL) Delisted Grant (A) +2,647 $0 EDGAR
2024-12-09 Nuvalent, Inc. (NUVL) Delisted Grant (A) +3,200 $0 EDGAR
2022-08-16 — Disp (D) −259,170 $0
2022-08-11 Epizyme, Inc. (EPZM) Delisted Mixed +76,110 $106.2K EDGAR
2022-03-21 Epizyme, Inc. (EPZM) Delisted Grant (A) — $0 EDGAR
2022-02-04 Epizyme, Inc. (EPZM) Delisted Grant (A) +87,500 $0 EDGAR
2021-08-18 Epizyme, Inc. (EPZM) Delisted Grant (A) +87,500 $0 EDGAR
2021-06-15 Epizyme, Inc. (EPZM) Delisted Grant (A) +8,060 $0 EDGAR
Showing 1–10 of 18
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.